Posted by Michael Wonder on 08 Jul 2025
Drug reimbursement panel approves iptacopan for PNH reimbursement, rejects danicopan over cost concerns
7 March 2025 - The Pharmaceutical Reimbursement Review Committee has made mixed decisions on the two medicines for paroxysmal nocturnal haemoglobinuria: Fabhalta (iptacopan) and Voydeya (danicopan).
On Thursday, HIRA announced the results of this year’s third PREC meeting.
